CR20250074A - Conjugados de fármaco-anticuerpo contra el factor tisular y usos de estos. - Google Patents

Conjugados de fármaco-anticuerpo contra el factor tisular y usos de estos.

Info

Publication number
CR20250074A
CR20250074A CR20250074A CR20250074A CR20250074A CR 20250074 A CR20250074 A CR 20250074A CR 20250074 A CR20250074 A CR 20250074A CR 20250074 A CR20250074 A CR 20250074A CR 20250074 A CR20250074 A CR 20250074A
Authority
CR
Costa Rica
Prior art keywords
tissue factor
antibody
drug conjugates
conjugates
factor antibody
Prior art date
Application number
CR20250074A
Other languages
English (en)
Inventor
Robyn M Barfield
Penelope M Drake
Maxine Bauzon
Tiffany Unsulangi
Seema Kantak
Brian Alan Mendelsohn
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR20250074A publication Critical patent/CR20250074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona estructuras de conjugados de anticuerpo-fármaco anti-factor tisular. Las estructuras de conjugados de anticuerpo-fármaco incluyen un enlazador ramificado, donde dos o más cargas activas por enlazador ramificado se unen a un anticuerpo. Además, la descripción también abarca compuestos y métodos para la producción de dichos conjugados. Además, la descripción también abarca métodos de uso de los conjugados.
CR20250074A 2022-09-07 2023-09-06 Conjugados de fármaco-anticuerpo contra el factor tisular y usos de estos. CR20250074A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263404447P 2022-09-07 2022-09-07
US202363498233P 2023-04-25 2023-04-25
PCT/US2023/073516 WO2024054821A2 (en) 2022-09-07 2023-09-06 Tissue factor antibody-drug conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CR20250074A true CR20250074A (es) 2025-04-10

Family

ID=90191921

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250074A CR20250074A (es) 2022-09-07 2023-09-06 Conjugados de fármaco-anticuerpo contra el factor tisular y usos de estos.

Country Status (15)

Country Link
EP (1) EP4583922A2 (es)
JP (1) JP2025530129A (es)
KR (1) KR20250060248A (es)
CN (1) CN120129535A (es)
AU (1) AU2023338206A1 (es)
CA (1) CA3265517A1 (es)
CL (1) CL2025000595A1 (es)
CO (1) CO2025003047A2 (es)
CR (1) CR20250074A (es)
DO (1) DOP2025000050A (es)
IL (1) IL319205A (es)
MX (1) MX2025002614A (es)
PE (1) PE20251256A1 (es)
TW (1) TW202423991A (es)
WO (1) WO2024054821A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12540197B2 (en) 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007077A (es) * 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
BR112023014205A2 (pt) * 2021-01-15 2023-10-03 Scherer Technologies Llc R P Conjugados anticorpo-fármaco de camptotecina e métodos de uso dos mesmos
KR20250024875A (ko) * 2022-05-13 2025-02-19 엑셀리시스, 인코포레이티드 5t4 항체-약물 접합체 및 이의 용도

Also Published As

Publication number Publication date
CO2025003047A2 (es) 2025-03-27
DOP2025000050A (es) 2025-04-08
JP2025530129A (ja) 2025-09-11
KR20250060248A (ko) 2025-05-07
WO2024054821A2 (en) 2024-03-14
WO2024054821A3 (en) 2024-04-11
CL2025000595A1 (es) 2025-05-02
CN120129535A (zh) 2025-06-10
PE20251256A1 (es) 2025-05-06
AU2023338206A1 (en) 2025-03-06
MX2025002614A (es) 2025-04-02
CA3265517A1 (en) 2024-03-14
IL319205A (en) 2025-04-01
EP4583922A2 (en) 2025-07-16
TW202423991A (zh) 2024-06-16

Similar Documents

Publication Publication Date Title
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
CO2021004032A2 (es) Derivado de dinucleótido cíclico novedoso y su conjugado anticuerpo-fármaco
AR121695A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos
CO2025003047A2 (es) Conjugados de fármaco-anticuerpo contra el factor tisular y usos de estos
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
ECSP23034914A (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
CL2024000286A1 (es) Herboxidieno de conjugados de anticuerpo - fármaco y métodos de uso
CR20190296A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
BR112022019042A2 (pt) Método de preparação para conjugado anticorpo-fármaco
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2024006160A2 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
CO2025008047A2 (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
CO2025001468A2 (es) Compuestos citotóxicos y conjugados de los mismos
CL2025001398A1 (es) Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
MX2022003044A (es) Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
CO2025010841A2 (es) Conectores, conectores-fármaco, conjugados de los mismos y métodos para su uso
UY38265A (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
MX2022004341A (es) Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.
BR112023014215A2 (pt) Ligantes de éster de clivagem dupla para conjugados anticorpo-fármaco
MX2022009753A (es) Composiciones y metodos para el tratamiento de la enfermedad de pompe.
AR132362A1 (es) Conjugados que comprenden enlazadores escindibles
DOP2026000016A (es) Conjugados de fármaco-anticuerpo del receptor de membrana de la tirosina-proteína cinasa (ror) activable y sus usos
AR117686A1 (es) Modulador de empalme de herboxidieno de conjugados de anticuerpo-fármaco y métodos de uso
AR117405A1 (es) Uso de conjugados anticuerpo-fármaco que comprenden agentes que alteran la tubulina para tratar tumores sólidos
AR134425A1 (es) Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos